Pharmacology in the Catheterization Laboratory
Herausgeber: Waksman, Ron, Ajani, Andrew
Pharmacology in the Catheterization Laboratory
Herausgeber: Waksman, Ron, Ajani, Andrew
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Cardiologists today prescribe medications with complex mechanisms of action, pharmacokinetics, indications, contraindications and drug-frug interactions; many of which were not available when today s practitioners were in training. This book was written to meet the growing demand for complete, detailed and accurate cardiac pharmacology information. This in-depth examination of the specific types of pharmacological agents used in the cardiac catheterization lab - as well as those routinely prescribed for cardiac patients - evaluates drugs with respect to their:
Cellular and physiological…mehr
Andere Kunden interessierten sich auch für
- Antiplatelet Therapy in Cardiovascular Disease98,99 €
- Ever D. GrechABC of Interventional Cardiology51,99 €
- Transcatheter Mitral Valve Therapies188,99 €
- Aortic Valve Transcatheter Intervention190,99 €
- Chronic Total Occlusions183,99 €
- Interventional Cardiology355,99 €
- Ron WaksmanBifurcation Stenting136,99 €
-
-
-
Cardiologists today prescribe medications with complex mechanisms of action, pharmacokinetics, indications, contraindications and drug-frug interactions; many of which were not available when today s practitioners were in training. This book was written to meet the growing demand for complete, detailed and accurate cardiac pharmacology information.
This in-depth examination of the specific types of pharmacological agents used in the cardiac catheterization lab - as well as those routinely prescribed for cardiac patients - evaluates drugs with respect to their:
Cellular and physiological actions
Prescribed usage
Dosages
Adverse reactions
Cautions
Common routes of administration
Opening chapters discuss anticoagulation therapies and antiplatelet therapies. later chapters cover percutaneous coronary intervention and its possible complications, post-procedure pharmacotherapy, and anticoagulation anomalies.
Drawing on the expertise of contributors from around the world, Pharmacology in the Catheterization Laboratory is the perfect blend of evidence and experience.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
This in-depth examination of the specific types of pharmacological agents used in the cardiac catheterization lab - as well as those routinely prescribed for cardiac patients - evaluates drugs with respect to their:
Cellular and physiological actions
Prescribed usage
Dosages
Adverse reactions
Cautions
Common routes of administration
Opening chapters discuss anticoagulation therapies and antiplatelet therapies. later chapters cover percutaneous coronary intervention and its possible complications, post-procedure pharmacotherapy, and anticoagulation anomalies.
Drawing on the expertise of contributors from around the world, Pharmacology in the Catheterization Laboratory is the perfect blend of evidence and experience.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Wiley & Sons
- 1. Auflage
- Seitenzahl: 400
- Erscheinungstermin: 1. Januar 2010
- Englisch
- Abmessung: 254mm x 180mm x 25mm
- Gewicht: 1089g
- ISBN-13: 9781405157049
- ISBN-10: 1405157046
- Artikelnr.: 27874367
- Verlag: Wiley & Sons
- 1. Auflage
- Seitenzahl: 400
- Erscheinungstermin: 1. Januar 2010
- Englisch
- Abmessung: 254mm x 180mm x 25mm
- Gewicht: 1089g
- ISBN-13: 9781405157049
- ISBN-10: 1405157046
- Artikelnr.: 27874367
Ron Waksman, MD, FACC. Associate Director, Division of Cardiology, Washington Hospital Center (WHC) and Director of Experimental Angioplasty & Emerging Technologies, Cardiovascular Research Institute(CRI) at WHC, Washington, DC USA. Andrew E. Ajani, Australia.
Ron Waksman, Andrew E. Ajani. 0.0 Elective PCI. 0.1 Optimal antithrombotic
therapy. 0.1.1 Unfractionated heparin and ACT monitoring. 0.1.2 Alternative
to unfractionated heparin. 0.1.2.1 LMWH. 0.1.2.2 direct thrombin inhibitor
(bivarlirudin). 0.1.2.3 direct Xa antagonist (fondaparinux). 0.2 Optimal
antiplatelet therapy. 0.2.1 Dual aspirin and thienopyridine therapy. -
pre-treatment and dose. 0.2.2 When to use GP2B3A inhibitor and which one to
use. - abciximab, tirofiban, eptifibatide. 0.2.3 Duration of Antiplatelet
therapy with drug-eluting vs. bare-metal stents. 1.0 High risk PCI. 1.1 ACS
(non ST elevation). 1.1.1 Upstream GP2B3A inhibitors. 1.1.2 Timing, loading
dose and duration of clopidogrel therapy. 1.2 Diabetes mellitus. 1.2.1
Peri-procedural management. 1.3 Renal dysfunction. 1.3.1 Renal protective
agents. - IV hydration, N-acetylcysteine, bicarbonate, fenoldopam. -
Timing, route of administration and duration. 1.3.2 Radiocontrast induced
nephropathy. 1.3.2.1 Ideal contrast agent. 1.3.3 Additional risk with other
medications. - ACE inhibitors, NSAIDS, hypotensive medications (e.g.
nitrates, BBlockers). 1.4 Cardiogenic shock. 1.4.1 Inotropic support. -
adrenaline, noradrenaline, dopamine, dobutamine, milrinone, levosimendan,
metaraminol. - summary of when to use which agent (ref. ACC/AHA STEMI
guidelines). 1.4.2 Anticoagulation support for mechanical devices. - IABP,
LVAD, Tandem Heart, Impaler etc. 2.0 Acute STEMI PCI. 2.1 Primary. -
summary of optimal anticoagulation, GP2B3A, antiplatelet therapy (aspirin,
clopidogrel). 2.2 Rescue. - summary of optimal anticoagulation, GP2B3A,
antiplatelet therapy (aspirin, clopidogrel). 2.3 Facilitated. - summary of
optimal anticoagulation, GP2B3A and lytic combinations in recent trials.
2.4 Adjunctive therapies. 2.4.1 GIK (glucose-insulin-potassium). 2.4.2
Complement inhibitor (Pexiluzimab). 2.4.3 Intracoronary vs. intravenous
GP2B3A inhibitor. 2.4.4 High dose tirofiban. (Standard dose GP2B3A
inhibitors for STEMI discussed in 2.1 and 2.2). 3.0 Optimal thrombolytic
therapy (as primary therapy for STEMI). - alteplase, reteplase,
streptokinase, or tenecteplase. 4.0 Special considerations in PCI. 4.1
Coronary spasm. 4.2 No reflow phenomenon. - IV GTN, GP2B3A inhibitor,
nitroprusside, adenosine, verapamil, nicorandil. 4.3 Agents to optimise
access of radial artery approach (i.e. nitrates, verapamil). 4.4 Arrhythmia
Management. 4.4.1 Tachyarrhythmias management. - IV lignocaine, amiodarone,
etc. 4.4.2 Bradyarrhythmias management. - IV atropine, adrenalin,
indications for temporary pacing wire. 4.5 Coronary perforations. 4.5.1
Reversal of anticoagulation. - protamine. 4.5.2 Platelet and transfusion of
blood products. 4.6 Oral anticoagulation issues in PCI. 4.6.1 Management of
patients on anticoagulation undergoing diagnostic catheterisation and PCI.
- prosthetic heart valves, AF and other indications. - use of UFH and LMWH
as bridging therapy. - when to restart oral anticoagulation post procedure.
4.6.2 Indications for anticoagulation post PCI. - LV thrombus. - large
anterior myocardial infarction. - triple (aspirin, clopidogrel and
warfarin) vs. dual therapy. 4.7 Role of Antibiotic prophylaxis in PCI. 5.0
Post procedural pharmacotherapy. 5.1 Role of statins, beta-blocker, ACE
inhibitors, aldosterone antagonist (epleronone). 5.1.1 ACS (include
STEMI/NSTEMI). 5.1.2 Elective PCI. 6.0 Special considerations with
antiplatelet therapy. 6.1 Antiplatelet therapy resistance: definition,
diagnosis and clinical implications. 6.2 Potential drug-drug interactions.
6.2.1 Clopidogrel and statins. 6.2.2 Aspirin and ibuprofen. 6.2.3 COX-2
inhibitors in patients with coronary artery disease. 6.3 Clopidogrel use in
patients requiring CABGS. 6.4 Thrombocytopenia post PCI. 6.4.1 HITTS. 6.4.2
GP2B3A risk. 6.5 Novel antiplatelet therapy. - Prasugrel etc. 7.0
Pharmacotherapy for in-stent restenosis. 7.1 Drug-eluting stents. 7.1.1
Sirolimus. 7.1.2 Paclitaxel. 7.1.3 Other agents (ABT-578). 7.1.4 Oral
agents to prevent ISR (Oral Sirolimus, Glitazones). 8.0 Novel
pharmacotherapy and PCI. APPENDIX. - Listing of generic drug names in
alphabetical order with 1 page summary sheet on each drug. o Indications
and contraindications. o Dose and formulations. o Adverse reactions. o Drug
interactions
therapy. 0.1.1 Unfractionated heparin and ACT monitoring. 0.1.2 Alternative
to unfractionated heparin. 0.1.2.1 LMWH. 0.1.2.2 direct thrombin inhibitor
(bivarlirudin). 0.1.2.3 direct Xa antagonist (fondaparinux). 0.2 Optimal
antiplatelet therapy. 0.2.1 Dual aspirin and thienopyridine therapy. -
pre-treatment and dose. 0.2.2 When to use GP2B3A inhibitor and which one to
use. - abciximab, tirofiban, eptifibatide. 0.2.3 Duration of Antiplatelet
therapy with drug-eluting vs. bare-metal stents. 1.0 High risk PCI. 1.1 ACS
(non ST elevation). 1.1.1 Upstream GP2B3A inhibitors. 1.1.2 Timing, loading
dose and duration of clopidogrel therapy. 1.2 Diabetes mellitus. 1.2.1
Peri-procedural management. 1.3 Renal dysfunction. 1.3.1 Renal protective
agents. - IV hydration, N-acetylcysteine, bicarbonate, fenoldopam. -
Timing, route of administration and duration. 1.3.2 Radiocontrast induced
nephropathy. 1.3.2.1 Ideal contrast agent. 1.3.3 Additional risk with other
medications. - ACE inhibitors, NSAIDS, hypotensive medications (e.g.
nitrates, BBlockers). 1.4 Cardiogenic shock. 1.4.1 Inotropic support. -
adrenaline, noradrenaline, dopamine, dobutamine, milrinone, levosimendan,
metaraminol. - summary of when to use which agent (ref. ACC/AHA STEMI
guidelines). 1.4.2 Anticoagulation support for mechanical devices. - IABP,
LVAD, Tandem Heart, Impaler etc. 2.0 Acute STEMI PCI. 2.1 Primary. -
summary of optimal anticoagulation, GP2B3A, antiplatelet therapy (aspirin,
clopidogrel). 2.2 Rescue. - summary of optimal anticoagulation, GP2B3A,
antiplatelet therapy (aspirin, clopidogrel). 2.3 Facilitated. - summary of
optimal anticoagulation, GP2B3A and lytic combinations in recent trials.
2.4 Adjunctive therapies. 2.4.1 GIK (glucose-insulin-potassium). 2.4.2
Complement inhibitor (Pexiluzimab). 2.4.3 Intracoronary vs. intravenous
GP2B3A inhibitor. 2.4.4 High dose tirofiban. (Standard dose GP2B3A
inhibitors for STEMI discussed in 2.1 and 2.2). 3.0 Optimal thrombolytic
therapy (as primary therapy for STEMI). - alteplase, reteplase,
streptokinase, or tenecteplase. 4.0 Special considerations in PCI. 4.1
Coronary spasm. 4.2 No reflow phenomenon. - IV GTN, GP2B3A inhibitor,
nitroprusside, adenosine, verapamil, nicorandil. 4.3 Agents to optimise
access of radial artery approach (i.e. nitrates, verapamil). 4.4 Arrhythmia
Management. 4.4.1 Tachyarrhythmias management. - IV lignocaine, amiodarone,
etc. 4.4.2 Bradyarrhythmias management. - IV atropine, adrenalin,
indications for temporary pacing wire. 4.5 Coronary perforations. 4.5.1
Reversal of anticoagulation. - protamine. 4.5.2 Platelet and transfusion of
blood products. 4.6 Oral anticoagulation issues in PCI. 4.6.1 Management of
patients on anticoagulation undergoing diagnostic catheterisation and PCI.
- prosthetic heart valves, AF and other indications. - use of UFH and LMWH
as bridging therapy. - when to restart oral anticoagulation post procedure.
4.6.2 Indications for anticoagulation post PCI. - LV thrombus. - large
anterior myocardial infarction. - triple (aspirin, clopidogrel and
warfarin) vs. dual therapy. 4.7 Role of Antibiotic prophylaxis in PCI. 5.0
Post procedural pharmacotherapy. 5.1 Role of statins, beta-blocker, ACE
inhibitors, aldosterone antagonist (epleronone). 5.1.1 ACS (include
STEMI/NSTEMI). 5.1.2 Elective PCI. 6.0 Special considerations with
antiplatelet therapy. 6.1 Antiplatelet therapy resistance: definition,
diagnosis and clinical implications. 6.2 Potential drug-drug interactions.
6.2.1 Clopidogrel and statins. 6.2.2 Aspirin and ibuprofen. 6.2.3 COX-2
inhibitors in patients with coronary artery disease. 6.3 Clopidogrel use in
patients requiring CABGS. 6.4 Thrombocytopenia post PCI. 6.4.1 HITTS. 6.4.2
GP2B3A risk. 6.5 Novel antiplatelet therapy. - Prasugrel etc. 7.0
Pharmacotherapy for in-stent restenosis. 7.1 Drug-eluting stents. 7.1.1
Sirolimus. 7.1.2 Paclitaxel. 7.1.3 Other agents (ABT-578). 7.1.4 Oral
agents to prevent ISR (Oral Sirolimus, Glitazones). 8.0 Novel
pharmacotherapy and PCI. APPENDIX. - Listing of generic drug names in
alphabetical order with 1 page summary sheet on each drug. o Indications
and contraindications. o Dose and formulations. o Adverse reactions. o Drug
interactions
Ron Waksman, Andrew E. Ajani. 0.0 Elective PCI. 0.1 Optimal antithrombotic
therapy. 0.1.1 Unfractionated heparin and ACT monitoring. 0.1.2 Alternative
to unfractionated heparin. 0.1.2.1 LMWH. 0.1.2.2 direct thrombin inhibitor
(bivarlirudin). 0.1.2.3 direct Xa antagonist (fondaparinux). 0.2 Optimal
antiplatelet therapy. 0.2.1 Dual aspirin and thienopyridine therapy. -
pre-treatment and dose. 0.2.2 When to use GP2B3A inhibitor and which one to
use. - abciximab, tirofiban, eptifibatide. 0.2.3 Duration of Antiplatelet
therapy with drug-eluting vs. bare-metal stents. 1.0 High risk PCI. 1.1 ACS
(non ST elevation). 1.1.1 Upstream GP2B3A inhibitors. 1.1.2 Timing, loading
dose and duration of clopidogrel therapy. 1.2 Diabetes mellitus. 1.2.1
Peri-procedural management. 1.3 Renal dysfunction. 1.3.1 Renal protective
agents. - IV hydration, N-acetylcysteine, bicarbonate, fenoldopam. -
Timing, route of administration and duration. 1.3.2 Radiocontrast induced
nephropathy. 1.3.2.1 Ideal contrast agent. 1.3.3 Additional risk with other
medications. - ACE inhibitors, NSAIDS, hypotensive medications (e.g.
nitrates, BBlockers). 1.4 Cardiogenic shock. 1.4.1 Inotropic support. -
adrenaline, noradrenaline, dopamine, dobutamine, milrinone, levosimendan,
metaraminol. - summary of when to use which agent (ref. ACC/AHA STEMI
guidelines). 1.4.2 Anticoagulation support for mechanical devices. - IABP,
LVAD, Tandem Heart, Impaler etc. 2.0 Acute STEMI PCI. 2.1 Primary. -
summary of optimal anticoagulation, GP2B3A, antiplatelet therapy (aspirin,
clopidogrel). 2.2 Rescue. - summary of optimal anticoagulation, GP2B3A,
antiplatelet therapy (aspirin, clopidogrel). 2.3 Facilitated. - summary of
optimal anticoagulation, GP2B3A and lytic combinations in recent trials.
2.4 Adjunctive therapies. 2.4.1 GIK (glucose-insulin-potassium). 2.4.2
Complement inhibitor (Pexiluzimab). 2.4.3 Intracoronary vs. intravenous
GP2B3A inhibitor. 2.4.4 High dose tirofiban. (Standard dose GP2B3A
inhibitors for STEMI discussed in 2.1 and 2.2). 3.0 Optimal thrombolytic
therapy (as primary therapy for STEMI). - alteplase, reteplase,
streptokinase, or tenecteplase. 4.0 Special considerations in PCI. 4.1
Coronary spasm. 4.2 No reflow phenomenon. - IV GTN, GP2B3A inhibitor,
nitroprusside, adenosine, verapamil, nicorandil. 4.3 Agents to optimise
access of radial artery approach (i.e. nitrates, verapamil). 4.4 Arrhythmia
Management. 4.4.1 Tachyarrhythmias management. - IV lignocaine, amiodarone,
etc. 4.4.2 Bradyarrhythmias management. - IV atropine, adrenalin,
indications for temporary pacing wire. 4.5 Coronary perforations. 4.5.1
Reversal of anticoagulation. - protamine. 4.5.2 Platelet and transfusion of
blood products. 4.6 Oral anticoagulation issues in PCI. 4.6.1 Management of
patients on anticoagulation undergoing diagnostic catheterisation and PCI.
- prosthetic heart valves, AF and other indications. - use of UFH and LMWH
as bridging therapy. - when to restart oral anticoagulation post procedure.
4.6.2 Indications for anticoagulation post PCI. - LV thrombus. - large
anterior myocardial infarction. - triple (aspirin, clopidogrel and
warfarin) vs. dual therapy. 4.7 Role of Antibiotic prophylaxis in PCI. 5.0
Post procedural pharmacotherapy. 5.1 Role of statins, beta-blocker, ACE
inhibitors, aldosterone antagonist (epleronone). 5.1.1 ACS (include
STEMI/NSTEMI). 5.1.2 Elective PCI. 6.0 Special considerations with
antiplatelet therapy. 6.1 Antiplatelet therapy resistance: definition,
diagnosis and clinical implications. 6.2 Potential drug-drug interactions.
6.2.1 Clopidogrel and statins. 6.2.2 Aspirin and ibuprofen. 6.2.3 COX-2
inhibitors in patients with coronary artery disease. 6.3 Clopidogrel use in
patients requiring CABGS. 6.4 Thrombocytopenia post PCI. 6.4.1 HITTS. 6.4.2
GP2B3A risk. 6.5 Novel antiplatelet therapy. - Prasugrel etc. 7.0
Pharmacotherapy for in-stent restenosis. 7.1 Drug-eluting stents. 7.1.1
Sirolimus. 7.1.2 Paclitaxel. 7.1.3 Other agents (ABT-578). 7.1.4 Oral
agents to prevent ISR (Oral Sirolimus, Glitazones). 8.0 Novel
pharmacotherapy and PCI. APPENDIX. - Listing of generic drug names in
alphabetical order with 1 page summary sheet on each drug. o Indications
and contraindications. o Dose and formulations. o Adverse reactions. o Drug
interactions
therapy. 0.1.1 Unfractionated heparin and ACT monitoring. 0.1.2 Alternative
to unfractionated heparin. 0.1.2.1 LMWH. 0.1.2.2 direct thrombin inhibitor
(bivarlirudin). 0.1.2.3 direct Xa antagonist (fondaparinux). 0.2 Optimal
antiplatelet therapy. 0.2.1 Dual aspirin and thienopyridine therapy. -
pre-treatment and dose. 0.2.2 When to use GP2B3A inhibitor and which one to
use. - abciximab, tirofiban, eptifibatide. 0.2.3 Duration of Antiplatelet
therapy with drug-eluting vs. bare-metal stents. 1.0 High risk PCI. 1.1 ACS
(non ST elevation). 1.1.1 Upstream GP2B3A inhibitors. 1.1.2 Timing, loading
dose and duration of clopidogrel therapy. 1.2 Diabetes mellitus. 1.2.1
Peri-procedural management. 1.3 Renal dysfunction. 1.3.1 Renal protective
agents. - IV hydration, N-acetylcysteine, bicarbonate, fenoldopam. -
Timing, route of administration and duration. 1.3.2 Radiocontrast induced
nephropathy. 1.3.2.1 Ideal contrast agent. 1.3.3 Additional risk with other
medications. - ACE inhibitors, NSAIDS, hypotensive medications (e.g.
nitrates, BBlockers). 1.4 Cardiogenic shock. 1.4.1 Inotropic support. -
adrenaline, noradrenaline, dopamine, dobutamine, milrinone, levosimendan,
metaraminol. - summary of when to use which agent (ref. ACC/AHA STEMI
guidelines). 1.4.2 Anticoagulation support for mechanical devices. - IABP,
LVAD, Tandem Heart, Impaler etc. 2.0 Acute STEMI PCI. 2.1 Primary. -
summary of optimal anticoagulation, GP2B3A, antiplatelet therapy (aspirin,
clopidogrel). 2.2 Rescue. - summary of optimal anticoagulation, GP2B3A,
antiplatelet therapy (aspirin, clopidogrel). 2.3 Facilitated. - summary of
optimal anticoagulation, GP2B3A and lytic combinations in recent trials.
2.4 Adjunctive therapies. 2.4.1 GIK (glucose-insulin-potassium). 2.4.2
Complement inhibitor (Pexiluzimab). 2.4.3 Intracoronary vs. intravenous
GP2B3A inhibitor. 2.4.4 High dose tirofiban. (Standard dose GP2B3A
inhibitors for STEMI discussed in 2.1 and 2.2). 3.0 Optimal thrombolytic
therapy (as primary therapy for STEMI). - alteplase, reteplase,
streptokinase, or tenecteplase. 4.0 Special considerations in PCI. 4.1
Coronary spasm. 4.2 No reflow phenomenon. - IV GTN, GP2B3A inhibitor,
nitroprusside, adenosine, verapamil, nicorandil. 4.3 Agents to optimise
access of radial artery approach (i.e. nitrates, verapamil). 4.4 Arrhythmia
Management. 4.4.1 Tachyarrhythmias management. - IV lignocaine, amiodarone,
etc. 4.4.2 Bradyarrhythmias management. - IV atropine, adrenalin,
indications for temporary pacing wire. 4.5 Coronary perforations. 4.5.1
Reversal of anticoagulation. - protamine. 4.5.2 Platelet and transfusion of
blood products. 4.6 Oral anticoagulation issues in PCI. 4.6.1 Management of
patients on anticoagulation undergoing diagnostic catheterisation and PCI.
- prosthetic heart valves, AF and other indications. - use of UFH and LMWH
as bridging therapy. - when to restart oral anticoagulation post procedure.
4.6.2 Indications for anticoagulation post PCI. - LV thrombus. - large
anterior myocardial infarction. - triple (aspirin, clopidogrel and
warfarin) vs. dual therapy. 4.7 Role of Antibiotic prophylaxis in PCI. 5.0
Post procedural pharmacotherapy. 5.1 Role of statins, beta-blocker, ACE
inhibitors, aldosterone antagonist (epleronone). 5.1.1 ACS (include
STEMI/NSTEMI). 5.1.2 Elective PCI. 6.0 Special considerations with
antiplatelet therapy. 6.1 Antiplatelet therapy resistance: definition,
diagnosis and clinical implications. 6.2 Potential drug-drug interactions.
6.2.1 Clopidogrel and statins. 6.2.2 Aspirin and ibuprofen. 6.2.3 COX-2
inhibitors in patients with coronary artery disease. 6.3 Clopidogrel use in
patients requiring CABGS. 6.4 Thrombocytopenia post PCI. 6.4.1 HITTS. 6.4.2
GP2B3A risk. 6.5 Novel antiplatelet therapy. - Prasugrel etc. 7.0
Pharmacotherapy for in-stent restenosis. 7.1 Drug-eluting stents. 7.1.1
Sirolimus. 7.1.2 Paclitaxel. 7.1.3 Other agents (ABT-578). 7.1.4 Oral
agents to prevent ISR (Oral Sirolimus, Glitazones). 8.0 Novel
pharmacotherapy and PCI. APPENDIX. - Listing of generic drug names in
alphabetical order with 1 page summary sheet on each drug. o Indications
and contraindications. o Dose and formulations. o Adverse reactions. o Drug
interactions